AI Consensus Investment Thesis
Lonza Group (LONN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Buy & Hold
Multiple horizons support ownership with measured follow-through.
1-Year
BUY650 CHF
+13.0%+13.5% incl. dividends5-Year
BUY1,051 CHF
+82.7%+86.8% incl. dividendsLatest flagship insight
Why Geopolitical Decoupling Is Creating A Massive Physical Bottleneck In Medicine
High consensus across reports indicates that legislative decoupling and aggressive capital expenditure are establishing an impenetrable Western manufacturing monopoly. While near-term free cash flow remains depressed due to heavy infrastructure investments, the long-term outlook is driven by a massive supply bottleneck for complex biological therapeutics.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The base-case investment thesis positions this asset as the foundational infrastructure layer for the next generation of global medicine. As generative artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry accelerates drug discovery, the primary bottleneck shifts from digital design to physical synthesis. This structural imbalance is compounded by Western legislative mandates that systematically restrict Chinese manufacturing capacity, forcing a massive rerouting of high-margin contracts to secure Western facilities. While near-term financial metrics are distorted by peak capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry and non-cash divestiture charges, the underlying operating engine remains highly resilient. As newly acquired and constructed facilities transition to commercial-scale utilization, the capital cycle will shift from intensive investment to a high-margin cash harvest.
Key insights
- Geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry via legislative mandates acts as a permanent structural moatstructural moatA durable competitive advantage protecting the business from market entrants and pricing pressure.View full glossary entry, redirecting global biopharma contracts to secure Western sites.
- The collision of rapid digital drug discovery with finite physical manufacturing capacity creates a highly lucrative, long-term capacity bottleneck.
- Peak capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry is tapering, setting the stage for a dramatic free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry inflection as facility utilization scales.
- A fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry with low leverage provides absolute insulation against restrictive monetary regimes and expensive debt.
- Near-term optical earnings distortions from divestitures and depreciation present a highly attractive entry point for long-term capital.
- Key risks include potential regulatory compliance failures at flagship facilities and slower-than-expected clinical pipeline progression.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The prevailing market consensus views the asset with extreme skepticism, focusing heavily on a highly distorted trailing price-to-earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry and negative near-term free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. The crowd and mainstream financial media treat the company as an optically expensive, capital-intensive legacy manufacturer suffering from a post-pandemic hangover and a prolonged biotech funding winter. Analysts frequently fixate on recent net losses and high capital-expenditure-to-revenue ratios, interpreting these strategic investments as value-destroying cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry rather than essential capacity building. Consequently, the conventional narrative advises avoiding the stock until turns positive, remaining blind to the massive physical capacity required for the imminent wave of advanced therapeutics.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's failure to distinguish between temporary accounting distortions and structural geopolitical advantages. The crowd misinterprets the massive capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry surge as a permanent drag on returns, completely overlooking that this infrastructure is perfectly timed to absorb a mandatory supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry shift. The US BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry is systematically dismantling Chinese manufacturing capacity in Western pipelines, creating a forced migration of high-margin contracts. While competitors face multi-year delays to build compliant facilities, this asset has immediate, validated capacity online. Furthermore, the market treats drug discovery as a software-only narrative, ignoring that digital molecules ultimately require highly regulated physical synthesis. By anchoring on trailing trough earnings distorted by one-off divestiture charges, the market is entirely mispricing a secure biological infrastructure monopolyinfrastructure monopolyA dominant provider of essential infrastructure protected by high capital, regulatory, network, or switching barriers.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? The convergence catalyst will trigger as peak capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry normalize and newly constructed facilities transition into active commercial production. This operational shift will coincide with the formal enforcement of the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry, forcing Western pharmaceutical companies to finalize long-term manufacturing contracts away from Chinese competitors. As these high-margin contracts are officially recognized, the company's free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry will inflect violently positive. Additionally, the removal of one-off divestiture charges from trailing twelve-month metrics will rapidly normalize the optical price-to-earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry, breaking algorithmic sell-screens and forcing institutional re-rating.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Growing Awareness
While there is high consensus that the asset is in a phase of growing awareness, minor disagreements exist regarding near-term sentiment. Some perspectives highlight a transition toward balanced sentiment as divestiture cash approaches, while others emphasize persistent fear anchored to trailing accounting losses and the ongoing biotech funding winter.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop presents a dual-sided setup. Restrictive monetary policy and elevated interest rates act as a near-term headwind by constraining venture capital funding for early-stage biotech clients. However, for a fully scaled, fortress-balance-sheet incumbent, this capital-scarce environment is a structural weapon that starves sub-scale competitors of the funding needed to build competing infrastructure. Simultaneously, the overarching geopolitical regime of supply-chain fragmentation and national security decoupling serves as an unstoppable tailwind, forcing price-insensitive global pharmaceutical companies to prioritize secure, Western-domiciled manufacturing capacity.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreements across the reports center on the exact timing of the free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry inflection and the near-term margin impact of facility integrations. Some perspectives assume a rapid recovery by late 2027 as the Vacaville site scales, while others model a more prolonged depreciation drag extending into 2028. Additionally, there is divergence regarding the severity of the biotech funding winter; some analyses project a near-term thaw that will rapidly release delayed clinical pipelines, whereas others expect high interest rates to constrain early-stage volume for a longer horizon.
Base-Case Forces
Event Risk ScoreVery Low15/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry Supply Decoupling | Regulatory | +35% | +45% | The US BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry and broader Western geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry are systematically removing Chinese manufacturing capacity from the global life-sciences supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry. This creates an immediate, government-mandated moat for Western incumbents. As biopharma companies rapidly sever ties with legacy Eastern partners, high-margin manufacturing contracts are being forcibly rerouted. This regulatory tailwind provides a massive, sustained upward catalyst that will drive long-term volume commitments and improve facility utilization rates across the network. |
| AI-Driven Molecular Pipeline Boom | Innovation And Product | +25% | +30% | Artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry is exponentially increasing the volume of novel drug molecules entering the clinical pipeline. However, software models cannot physically synthesize biological molecules. This creates a severe physical manufacturing bottleneck. As these AI-designed therapeutics transition into clinical and commercial scaling, demand for highly specialized, sterile bioreactor capacity will outstrip global supply. This structural shift guarantees that the order bookorder bookThe set of confirmed customer orders that have not yet been delivered or recognized as revenue.View full glossary entry will aggressively expand, directly driving long-term revenue growth. |
| Capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry to Free Cash Flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry Inflection | Capital Allocation | +22% | +40% | The company is exiting a period of intense capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry, having deployed over 20% of revenue into capacity expansion. While this heavy investment phase has depressed near-term free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, the completion of these facilities marks a major turning point. As these high-margin mammalian and biologics sites come online and transition to commercial utilization, will normalize. This S-curve inflections curve inflectionThe point where adoption shifts from slow early growth to rapid expansion, or begins to mature.View full glossary entry will violently flip the cash flow profile, driving massive generation. |
| Vacaville Capacity Activation and Scale | Competitive Positioning | +20% | +25% | The strategic acquisition of the Vacaville biologics site provides immediate, large-scale, FDA-approved manufacturing capacity exactly when the market is starved for it. While competitors face multi-year delays and capital risks to build greenfield facilities to accommodate the Chinese CDMOcontract development and manufacturing organizationContract development and manufacturing organization (CDMO) refers to a firm that provides outsourced development, production, and related services for drug or biotech programs.View full glossary entry exodus, this capacity is already online. This scale advantage preempts competition, allows the company to dictate contract terms, and ensures immediate revenue onboarding, steepening the earnings growth curve. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Warsh-Era Biotech Funding Squeeze | Macroeconomic And Macrofinancial | -15% | -12% | The persistent restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry and elevated interest rates are highly toxic to speculative, pre-revenue biotech companies. As venture capital funding dries up, smaller clinical-stage firms are delaying trials or facing bankruptcy. This funding squeeze shrinks the pipeline of early-stage contracts, reducing future blockbuster conversion rates. While commercial-stage contracts remain secure, the attrition at the bottom of the clinical funnel will exert a sustained downward drag on near-term volume growth. |
| Hormuz-Linked Energy and Input Inflationinput inflationAn increase in the cost of raw materials, components, labor, or energy used to produce goods and services.View full glossary entry | Macroeconomic And Macrofinancial | -10% | -12% | Biopharmaceutical manufacturing is highly energy-intensive and reliant on specialized global logistics. Regional energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry and supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry disruptions have structurally inflated European industrial power costs and created shortages in critical inputs like single-use plastics and helium. While contractual pass-through mechanisms protect long-term margins, the lag in implementing these surcharges creates near-term margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry and operational bottlenecks across European facilities. |
| Swiss Francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry Structural Premium | Macroeconomic And Macrofinancial | -8.0% | -10% | Operating from a Swiss cost base while generating a massive portion of revenue in US dollars and Euros exposes the company to a relentless currency mismatch. The structural strength of the Swiss Francswiss francThe Swiss franc (CHF) is the official currency of Switzerland and Liechtenstein.View full glossary entry, acting as a global safe-haven asset, systematically penalizes translated earnings and compresses operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. Unless effectively hedged, this currency drag serves as a permanent structural friction, pulling reported revenue and earnings growth downward. |
| Depreciation and Integration Margin Drag | Operational Efficiency | -5.0% | -10% | The massive physical buildout and the integration of large legacy facilities like the Vacaville site bring significant near-term operational friction. Retrofitting facilities and transitioning workforces cause temporary operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry. Furthermore, the massive asset base generates heavy depreciation schedules that will artificially suppress reported GAAP earnings per share, creating an optical valuation overhang that deters short-term momentum investors. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Catastrophic FDA Compliance Failure | 15% | -35% | Regulatory | The entire economic moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry relies on unassailable regulatory compliance and quality assurance. A severe compliance failure, contamination event, or critical FDA Warning Letter at a flagship facility would instantly halt production and batch releases. This would not only vaporize near-term revenue but irreparably damage client trust, triggering immediate contract cancellations and forcing sponsors to permanently diversify their supply chains. |
| Sovereign Pharma Price Controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry | 25% | -25% | Regulatory | The implementation of aggressive, sweeping price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry on major biological drugs by Western governments could trigger a catastrophic margin collapse for pharmaceutical innovators. This pricing pressure would instantly roll downhill, forcing sponsors to demand extreme fee compressionfee compressionDownward pressure on the fees a business can charge because of competition, regulation, bargaining power, or product standardization.View full glossary entry from manufacturers. This would break the margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry thesis and leave newly constructed, high-cost facilities heavily underutilized. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Total Competitor Blacklist | 35% | +25% | Regulatory | If Western governments accelerate BIOSECURE mandates into an immediate, un-grandfathered ban on all Chinese-linked manufacturers, pharmaceutical pipelines will face an existential crisis. This sudden capacity shock would trigger a frantic bidding war for secure Western production slots. The company would capture a disproportionate share of emergency contract migrations, allowing it to extract massive upfront reservation fees and lock in premium pricing. |
| Exclusive Mega-Blockbuster Contract | 40% | +20% | Sector And Industry | Securing an exclusive, decade-long commercial manufacturing agreement for a next-generation blockbuster drug, such as an oral GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry or breakthrough oncology therapeutic, would instantly validate the aggressive capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry strategy. This contract would guarantee maximum capacity utilization, pull forward the free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry inflection point, and transform cyclical clinical revenues into highly visible, long-duration cash flows. |
Company Financial Analysis
Lonza Group Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company's recent financial reports show a temporary drop in profits, including a large net loss at the end of 2025. However, this drop is mostly a backward-looking accounting distortion caused by one-time charges from selling off a lower-margin business and restructuring. Underneath this temporary noise, the core business is actually growing steadily. While current free cash flow is negative because the company is spending heavily to build massive new factories, this is a temporary phase. Most reports agree that as these new facilities start running and taking on contracts, earnings will bounce back strongly. There is some disagreement on how quickly this turnaround will happen, but the overall future outlook is highly positive as the company transitions into a highly focused, high-margin business.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | CHF 6.5B | CHF 949M | CHF -204M |
| 2024 | CHF 6.6B | CHF 636M | CHF -143M |
| 2023 | CHF 6.7B | CHF 654M | CHF -263M |
| 2022 | CHF 6.2B | CHF 1.2B | CHF -852M |
| 2021 | CHF 5.4B | CHF 2.9B | CHF -124M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | >100x | TTM | Native | CHF / CHF |
| 2024 | 30.8x | TTM | Native | CHF / CHF |
| 2023 | 12.2x | TTM | Native | CHF / CHF |
| 2022 | 27.7x | Annual | Native | CHF / CHF |
| 2021 | 19.3x | Annual | Native | CHF / CHF |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company's core profit margins remain highly robust, supported by strong pricing power and a shift toward complex, high-value biological medicines. Although recent profit margins look temporarily depressed on paper due to heavy depreciation and one-time restructuring costs, this is an optical illusion. As the company completes the sale of its lower-margin capsules division, its overall profit profile will structurally improve. The main point of agreement is that profit margins will expand significantly as newly built factories reach high utilization rates. While there is some minor disagreement on how much near-term energy inflation and labor costs in Western countries will drag on margins, the company's ability to pass these costs onto its clients ensures that its long-term profitability remains highly secure.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | CHF 1.4B | 21.2% | 14.5% |
| 2024 | CHF 964M | 14.7% | 9.7% |
| 2023 | CHF 880M | 13.1% | 9.7% |
| 2022 | CHF 1.5B | 24.8% | 19.5% |
| 2021 | CHF 851M | 15.7% | 54.4% |
Balance sheet and leverage
The company's balance sheet is an absolute fortress, offering incredible safety and financial power. With a very low debt-to-equity ratio and substantial cash reserves, the company is highly insulated from high interest rates and tight credit markets. This financial strength is a major competitive advantage, allowing the company to self-fund its massive factory expansions without needing to borrow expensive money or dilute shareholders. Furthermore, the upcoming multi-billion dollar cash injection from selling off its capsules division will make the balance sheet even stronger. All reports agree that this bulletproof financial position virtually eliminates refinancing risks and provides the company with the flexibility to survive economic downturns, buy back shares, or make strategic acquisitions of struggling competitors.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | CHF 4.5B | CHF 719M | CHF 3.8B net debt | 2.21x |
| 2024 | CHF 5.1B | CHF 1.7B | CHF 4B net debt | 1.52x |
| 2023 | CHF 3.1B | CHF 1.7B | CHF 1.7B net debt | 1.77x |
| 2022 | CHF 2.6B | CHF 2.2B | CHF 1.2B net debt | 1.85x |
| 2021 | CHF 2.7B | CHF 3.2B | CHF 1.2B net debt | 2.50x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is currently spending an exceptionally high portion of its revenue—over 20%—on building and expanding its high-tech factories. While short-term investors dislike this heavy spending because it temporarily eats up cash, it is actually a powerful strategic move. This aggressive investment is being used to build complex manufacturing facilities that competitors simply cannot afford to replicate, especially in a high-interest-rate environment. This massive physical footprint is designed to capture a wave of new business as drug companies are forced to move away from Chinese suppliers. Analysts agree that this heavy spending phase is currently peaking and will soon decline. Once the spending slows down and the new factories are fully utilized, the company is expected to generate massive amounts of free cash flow.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | CHF 1.4B | CHF 112M |
| 2024 | CHF 1.4B | CHF 118M |
| 2023 | CHF 1.6B | CHF 105M |
| 2022 | CHF 1.9B | CHF 95M |
| 2021 | CHF 1.3B | CHF 90M |
Quarterly Forecast Scenarios
Lonza Group Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in CHF; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (CHF) | Base Case Stock Price (CHF) | Bull Case Stock Price (CHF) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| 549.50 CHF | 585.76 CHF | 606.74 CHF | $736.09 | |
| 538.51 CHF | 609.04 CHF | 655.28 CHF | $724.14 | |
| 554.67 CHF | 628.40 CHF | 688.05 CHF | $713.57 | |
| 582.40 CHF | 650.19 CHF | 715.57 CHF | $723.38 | |
| 594.05 CHF | 672.36 CHF | 751.35 CHF | $716.61 | |
| 617.81 CHF | 699.51 CHF | 781.40 CHF | $738.34 | |
| 654.88 CHF | 723.41 CHF | 804.84 CHF | $746.91 | |
| 681.08 CHF | 740.35 CHF | 837.04 CHF | $771.93 | |
| 701.51 CHF | 762.03 CHF | 862.15 CHF | $782.73 | |
| 729.94 CHF | 793.86 CHF | 905.26 CHF | $807.31 | |
| 744.54 CHF | 825.18 CHF | 941.47 CHF | $822.72 | |
| 766.88 CHF | 842.75 CHF | 969.71 CHF | $846.10 | |
| 782.21 CHF | 855.68 CHF | 1,008 CHF | $852.53 | |
| 790.04 CHF | 890.18 CHF | 1,059 CHF | $882.91 | |
| 774.24 CHF | 909.93 CHF | 1,091 CHF | $900.46 | |
| 797.46 CHF | 941.29 CHF | 1,134 CHF | $922.67 | |
| 829.36 CHF | 965.71 CHF | 1,168 CHF | $935.91 | |
| 854.24 CHF | 996.57 CHF | 1,215 CHF | $952.30 | |
| 871.33 CHF | 1,019 CHF | 1,252 CHF | $976.28 | |
| 888.75 CHF | 1,051 CHF | 1,302 CHF | $1,002 |
Research Provenance
References & Context
This Lonza Group consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
annual: 2023-12-31–2025-12-31, 3 periods; quarterly: 2024-06-30–2025-12-31, 3 periods
Currencies cited: CHF, USD (quote CHF; primary reporting CHF; converted/valuation USD).